

ForPatients

by Roche

Alzheimer's Disease (AD)

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)

Trial Status
Recruiting

Trial Runs In
4 Countries

Trial Identifier
NCT07234942 2025-522101-37-00
BP45770

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This study aims to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics following administration of RO7812653 in participants with eAD.

Hoffmann-La Roche
Sponsor

Phase 1
Phase

NCT07234942 2025-522101-37-00 BP45770
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>=50 Years & <= 75 Years

Healthy Volunteers
No
